Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors
Sponsor: Can-Fite BioPharma
Listed as NCT01034306, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Can-Fite BioPharma, it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Can-Fite BioPharma
For direct contact, visit the study record on ClinicalTrials.gov .